LAUSR

Graphical abstract Figure. No Caption available. Abstract Ovarian carcinoma, the most common gynaecological cancer, is characterized by high lethality mainly due to late diagnosis and treatment failure. The efficacy of platinum drug‐based therapy in the disease is limited by the occurrence of drug resistance, a phenomenon often associated with increased metastatic potential. Because the Tyr‐kinase receptor Axl can be deregulated in ovarian carcinoma and plays a pro‐metastatic/anti‐apoptotic role, the aim of this study was to examine if Axl inhibition modulates drug resistance and aggressive features of ovarian carcinoma cells, using various pairs of cisplatin‐sensitive and ‐resistant cell lines. We found that mRNA and protein levels of Axl were increased in the platinum‐resistant IGROV‐1/Pt1 and IGROV‐1/OHP cell lines compared to the parental IGROV‐1 cells. IGROV‐1/Pt1 cells displayed increased migratory and invasive capabilities. When Axl was silenced, these cells exhibited reduced growth and invasive/migratory capabilities compared to control siRNA‐transfected cells, associated with decreased p38 and STAT3 phosphorylation. In keeping with this evidence, pharmacological inhibition of p38 and STAT3 decreased IGROV‐1/Pt1 invasive capability. Molecular inhibition of Axl did not sensitize IGROV‐1/Pt1 cells to cisplatin, but enhanced ErbB3 activation in IGROV‐1/Pt1 cells and suppressed the clonogenic capability of various ovarian carcinoma cell lines. The combination of cisplatin and AZD8931, a small molecule which inhibits ErbB3, produced a synergistic effect in IGROV‐1/Pt1 cells. Thus, Axl targeting per se reduces invasive capability of drug‐resistant cells, but sensitization to cisplatin requires the concomitant inhibition of additional survival pathways.